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Abstract
Background: Past clinical trials of antimicrobial treatment in soft tissue infections have focused
on non-standardized clinical and physiological outcome variables, and have not considered the
subjective experience of patients. The objective of this study was to develop a health-related quality
of life questionnaire (HRQL) for patients with extremity soft tissue infections (ESTI) for future use
in clinical trials.
Methods: The design of this study followed published guidelines and included item generation,
item reduction, and questionnaire preparation. Study subjects were consenting English-speaking
adults with acute ESTI requiring prescription of at least two days of outpatient intravenous
antibiotic therapy.
Results: A list of 49 items that adversely impact the quality of life of patients with ESTI was
generated by literature review, informal health professional feedback, and semi-structured
interviews with twenty patients. A listing of these items was then administered to 95 patients to
determine their relative importance on quality of life. A questionnaire was prepared that included
the twenty most important items with a 5-point Likert scale response. Questionnaire domains
included physical symptoms, problems performing their activities of daily living, impairment of their
emotional functioning, and difficulties in their social interactions as related to their ESTI. The final
questionnaire was pre-tested on a further ten patients and was named the ESTI-Score.
Conclusion: The ESTI-Score is a novel instrument designed to quantify the impact of ESTI on
quality of life. Future study is required to determine its validity and responsiveness before use as
an outcome measure in clinical trials.
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Background
Soft tissue infections (STI) are among the most common
infectious diseases requiring antibiotic treatment [1,2].
Despite their prevalence and importance, the optimal
treatment of STI's has not been well defined and consider-
able practice variation exists with respect to their manage-
ment. Although a wide variety of different antibiotic
classes, doses, durations, and methods of delivery have
been compared in clinical trials, few studies have shown
superiority of a given treatment [3]. While this may repre-
sent true clinical equipoise, it may also at least in part
reflect the insensitivity of outcome measures used. These
most commonly are non-standardized, disease-oriented,
physician assessments that may not adequately assess the
effect of therapy on the patient's subjective treatment
responses.
The use of Health Related Quality of Life (HRQL) scales
have been developed and demonstrated to be useful and
valid primary outcome measures in clinical trials in a
number of diseases not limited to asthma, rhinoconjunc-
tivitis, polycystic ovarian syndrome, and sleep apnea [4-
8]. Although quality of life measures have been developed
for chronic skin diseases, no HRQL clinical instrument
has been previously developed for acute extremity soft tis-
sue infections (ESTI) [9,10]. The objective of this study
was therefore to develop a disease-specific instrument to
measure the HRQL in patients with ESTI for future use in
clinical trials.
Methods
The study methodology followed previously published
guidelines for development of HRQL instruments
[11,12]. This process included item generation, item
reduction, questionnaire preparation, and questionnaire
pre-testing. The study protocol was reviewed and
approved by the Conjoint Health Research Ethics Board of
the University of Calgary. All subjects provided written
informed consent prior to participation. In addition to
questionnaire specific data, information was also col-
lected on patient demographics, co-morbidities, and the
treatments prescribed.
Study subjects
Patients with ESTI were enrolled from the Home
Parenteral Therapy Program (HPTP) clinic at the Peter
Lougheed Centre, Calgary, Alberta, Canada [13]. The
HPTP is an ambulatory clinic that serves patients with a
variety of infectious diseases requiring parenteral antimi-
crobial therapy. It is attended by fully certified infectious
disease specialists. Between November 2003 and May
2005 a convenience sample of patients was screened for
inclusion in the study. Patients were eligible for the study
if they met all of the following: 1) age at least eighteen at
the time of enrollment, 2) a diagnosis of ESTI made by an
HPTP physician, and 3) judged to require two or more
days of parenteral antibiotics by the HPTP physician.
Patients were excluded if they had any of the following: 1)
a chronic ulcer with no evidence of acute infection, 2) ina-
bility to speak and read English, 3) they were expected to
have poor adherence to the study protocol, or 4) they were
ineligible for the outpatient HPTP clinic (eg: admitted to
hospital). Patients were otherwise included in the study
irrespective of the severity of their illness, their co-morbid-
ities, or specific treatment regimen prescribed.
Item generation
The goal of this phase was to identify all possible items
that might adversely impact the quality of life of patients
with ESTI. These items were identified using four standard
methods: 1) a review of the published literature on the
clinical features of soft tissue infections, 2) a review of
HRQL scales in other medical conditions, 3) semi-struc-
tured interviews with a group of patients, and 4) the col-
lective experience of the study investigators and clinic
staff. The patient interviews were performed by trained
research nurses and took approximately 30 minutes. The
interview used open-ended questions to identify all possi-
ble areas of dysfunction (including physical symptoms,
activities of daily living, social and emotional well being)
that might be adversely affected by their ESTI.
Item reduction
The purpose of this phase was to identify the most impor-
tant items for patients with ESTI. Study participants inde-
pendently completed a questionnaire containing the
items identified in the item generation phase. They were
asked to identify which of the items were problems for
them. For items identified as being a problem, they were
asked to rate how important it was on a 5-point Likert
scale (ranging 1, not very important, to 5, extremely
important). The overall importance of each item was
determined by calculating its frequency importance prod-
uct (FIP). This was done by multiplying the frequency that
a particular item was reported as a problem by the mean
importance assigned to it [8].
Final questionnaire preparation
The twenty items with the highest FIPs were incorporated
into the final questionnaire. It was pre-tested on another
group of consenting patients to ensure that it was free of
grammatical errors and that individual items and the
overall format were easily understood.
Statistical considerations
Sample sizes were chosen a priori to be 20 patients for item
generation and 100 patients for item reduction based on
the guidelines of Kirshner and Guyatt [12]. All statistical
analysis was performed using Stata 8.0 (StataCorp, Col-
lege Station, Texas). Medians with interquartile rangesBMC Infectious Diseases 2006, 6:148 http://www.biomedcentral.com/1471-2334/6/148
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(IQR) were used to describe non-normally distributed
variables and means with standard deviations (SD) for
normally distributed variables. Group means were com-




Through interviews with twenty consenting patients with
ESTI, a review of the relevant literature, and the collective
experience of the study investigators, a list of 49 items was
generated for inclusion in the item reduction question-
naire and these are shown in Table 1.
Item reduction
Ninety-five patients were ultimately included in this stage.
One hundred and three patients were initially enrolled
but eight patients were subsequently excluded because
they did not maintain enrollment criteria. In six patients
the reason for exclusion was an alternate final diagnosis
[osteomyelitis (three); gout (two); deep venous thrombo-
sis (one)]. One patient was subsequently excluded
because he was recognized later to be seventeen years of
age at the time of enrollment. One patient was inadvert-
ently enrolled into the study on two separate occasions
and as such only the first presentation was analyzed.
The characteristics of the 95 analyzed patients and their
infections are summarized in Table 2. The patients were
most commonly middle-aged men with uncomplicated
cellulitis who were referred from the emergency depart-
ment.
The overall importance of each of the items was calculated
as frequency-importance-products and reported in Table
1.
Final questionnaire preparation
The twenty highest ranked items identified in item reduc-
tion (Table 1) were grouped into domains and included
in the final questionnaire. They were presented in a simi-
lar fashion as in the item reduction questionnaire. These
twenty items represent each of the HRQL domains includ-
ing symptoms (seven items), daily functioning (seven
items), emotional functioning (five items), and social
interactions (one item). The final questionnaire was pre-
tested on a group of ten patients. After filling out the sur-
vey independently they reviewed it with one of the study
investigators. No patient reported any difficulty in com-
pleting the questionnaire or interpreting the items.
The ESTI Score
The final ESTI-Score for a patient was calculated by adding
their scores for each item. The minimum and maximum
possible scores are zero and one hundred respectively. The
ESTI-Score was post hoc calculated for each of the patients
in the item reduction cohort. The mean ESTI-Score was
47.2 ± 21.1 points and their distribution is shown in Fig-
ure 1. No significant differences in mean scores were
observed overall between men and women, cellulitis ver-
sus other ESTI, or upper versus lower extremity site of
infection.
Discussion
We report the development of the first HRQL indicator for
use in patients with ESTI. This tool was developed using
established methodological guidelines and included a
diverse cohort of ambulatory adult patients with a variety
of soft tissue infections. It incorporated items representing
multiple areas of quality of life impairment including
physical symptoms, activities of daily living, emotional
and social functioning. When pre-tested on another group
of patients the final questionnaire was found to be
straightforward and easy to independently complete in
less than 10 minutes. In a post hoc analysis, of our patient
cohort, the ESTI-Score produced a broad range of near-
normally distributed values, potentially reflecting the
range of severity of ESTI in our patients.
Clinical trials of ESTI reported to date have largely used a
variety of disease-oriented outcome measures. Often a cat-
egorical assessment such as "cure" or "failure", "resolu-
tion of infection", or "improvement" is assigned by a
study investigator based on a non-standardized clinical
assessment [14-22]. Another approach has been to use
"microbiological eradication" or "microbiological persist-
ence" as an outcome measure [16,18-20]. The utility of
such an outcome measure is hampered by the fact that the
majority of soft tissue infections are culture negative or
will rapidly become culture negative even if sub-optimally
managed [23,24]. Others have attempted to quantify
improvement based on measurements of areas of inflam-
mation although this has not been validated and may not
be closely related to patients' symptoms [25]. While
patients' subjective experiences are often included in a
composite clinical assessment by a physician or study
investigator, the use of a HRQL measure allows actual
quantification of these experiences and the effect of treat-
ment.
Generic health measures such as the Medical Outcomes
Study 36-Item Short-Form Health Survey (SF-36) [26],
and the Nottingham Health Profile (NHP) [27], have
been developed to measure quality of life in a broad range
of illnesses. They may not, however, be able to detect the
subtle effects on quality of life specific to a particular dis-
ease. Specific HRQL scales have been developed and vali-
dated for other diseases and have been used as outcome
measures in clinical trials [4-8]. Tools, such as the "Skin-
dex," have been developed to evaluate the HRQL inBMC Infectious Diseases 2006, 6:148 http://www.biomedcentral.com/1471-2334/6/148
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Table 1: Items included in the Item Reduction Questionnaire. Overall importance of each item as measured by the Frequency 
Importance Product.
Item Frequency* Mean importance+ Overall importance++
Symptoms
Pain 0.95 3.69 3.49
Fever 0.42 3.23 1.36
Chills 0.51 3.06 1.55
Sweating 0.43 2.84 1.23
Loss of appetite 0.46 3.07 1.42
Nausea 0.27 2.63 0.72
Numbness 0.40 2.74 1.10
Swelling 0.92 3.88 3.56
Blistering 0.28 3.28 0.93
Fatigue 0.54 3.40 1.83
Trouble moving 0.75 3.47 2.59
Stiffness 0.60 3.28 1.97
Soreness 0.92 3.76 3.44
Pressure 0.66 3.43 2.28
Throbbing 0.61 3.36 2.05
Streaking 0.20 2.81 0.56
Discomfort in a distant body part 0.40 3.36 1.34
Discomfort caused by treatment of your infection 0.33 2.74 0.89
Daily Functioning
Doing your job 0.79 3.96 3.13
Walking 0.59 3.48 2.05
Bathing 0.62 3.45 2.14
Using the toilet 0.38 2.97 1.13
Driving 0.51 3.27 1.65
Changing clothes 0.64 2.98 1.92
Hobbies 0.51 3.10 1.57
Earning an income 0.54 4.08 2.19
Exercising 0.66 3.20 2.12
Falling asleep 0.62 3.53 2.19
Traveling 0.38 3.03 1.15
Emotional Functioning
Frustrated 0.68 3.46 2.37
Impatient 0.46 3.33 1.54
Irritable 0.57 3.09 1.76
Angry 0.28 3.27 0.93
Disappointed 0.61 3.18 1.94
Afraid 0.47 3.27 1.55
Annoyed 0.55 3.50 1.92
Embarrassed 0.31 2.77 0.85
Miserable 0.34 3.26 1.10
Depressed 0.28 2.67 0.76
Sad 0.34 2.75 0.93
Stressed 0.51 2.98 1.51
Exhausted 0.58 3.38 1.96
Inconvenienced 0.75 3.41 2.55
Social Interactions
Difficulty socializing because your infection is "disfiguring" 0.19 2.57 0.49
Difficulty getting out of the house 0.41 3.21 1.32
Less desire to socialize than usual 0.40 3.11 1.24
You are inconveniencing your friends and family 0.56 3.37 1.88
Difficulty being physically intimate with your partner 0.36 3.56 1.27
Difficult being emotionally intimate with your partner 0.24 3.33 0.81
*Frequency of study participants reporting item as a problem (maximum = 1.0)
+Mean importance assigned to item if reported as a problem (maximum = 5.0)
++Frequency importance product (frequency × mean importance) (maximum = 5.0)
NB: The twenty highest ranking items are in bold font and were included in the final questionnaire and calculation of the ESTI score.BMC Infectious Diseases 2006, 6:148 http://www.biomedcentral.com/1471-2334/6/148
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chronic dermatologic conditions but are not applicable to
acute soft tissue infections [9,10]. The ESTI-Score repre-
sents the first standardized clinical instrument to measure
the areas of HRQL impairment important to patients with
ESTI.
As a result of the ESTI-Score being developed using a
cohort of patients, it does have face and content validity.
However, there are a number of limitations of the current
study. First, it requires further prospective assessment in
another cohort of ESTI patients prior to being used as a
primary outcome measure in clinical trials. Areas to be
assessed include its reproducibility in patients with a sta-
ble disease state, its responsiveness to changes in infection
severity, and its relationship to other markers of disease
severity. Second, the ESTI-Score was derived from a group
of North American adult patients receiving parenteral
antibiotics at a single outpatient parenteral therapy clinic.
Patients with mild disease were excluded based on the
requirement for at least two days of parenteral therapy
and only English speaking patients were studied. Whether
it will be generalizable to adult patients in other outpa-
tient settings in other regions remains to be seen. Third,
while ESTI may have subsequent chronic impairment on
quality of life, they typically are acute conditions that
resolve over weeks or months and in most cases will not
have a major effect on an individual's quality of life dur-
ing their lifetime. The ESTI-Score may therefore represent
more of an acute comprehensive disease severity index
than a traditional measure of quality of life.
Conclusion
We report the development of the ESTI-Score that is
designed to quantify patients subjective experiences asso-
ciated with having an ESTI. Future studies are needed to
validate this HRQL instrument in another cohort of adult
ESTI patients so that it may be used as an important out-
come measure in future clinical trials evaluating manage-
ment strategies for ESTI.
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Table 2: Characteristics of 95 patients with ESTI included in the item reduction phase.
Characteristic Number
Mean years of age (SD) 47.5 (14.3)
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Referral location (%)
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Peripheral Vascular Disease 7 (7.3)
Immunosuppression 10 (10.5)




Septic bursitis 12 (12.6)
Septic tenosynovitis 3 (3.2)
Abscess 3 (3.2)
Location of ESTI (%)
Upper extremity 36 (37.9)
Lower extremity 59 (62.1)
Median duration of symptoms at time of survey (interquartile range) 4 (2–7)
Median days of intravenous antibiotics (interquartile range) 4 (3–6)
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